Abstract
We experienced a 78-year-old woman who was diagnosed with hereditary transthyretin cardiac amyloidosis and administered patisiran for advanced heart failure refractory to tafamidis. The levels of N-terminal pro B-type natriuretic peptide and left ventricular mass index decreased following the six-month patisiran treatment without any complications. Patisiran might be a promising disease-modifying drug for hereditary transthyretin cardiac amyloidosis even in its advanced stage, although further evaluation in a large cohort is warranted.
| Original language | English |
|---|---|
| Pages (from-to) | 177-180 |
| Number of pages | 4 |
| Journal | Journal of Cardiology Cases |
| Volume | 23 |
| Issue number | 4 |
| DOIs | |
| State | Published - 2021/04 |
Keywords
- Heart failure with preserved ejection fraction
- Transthyretin cardiac amyloidosis
- siRNA
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine